Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — H.C. Wainwright 24th Annual Global Investment Conference (September 2022)
47 slides from Puma Biotechnology's conference presentation, September 2022
Slide 1: Puma Biotechnology
Puma Biotechnology H.C. Wainwright 24th Annual Global Investment Conference September 2022
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: Product Pipeline
Product Pipeline Neratinib across the breast cancer therapy spectrum Phase I Phase II Phase III Registration Approval HER2+ Breast Cancer Extended adjuvant ExteNET (Phase III HER2+ EBC*) Neratinib monotherapy CONTROL Metastatic NALA (Phase III 3rd Line HER2+ MBC**) Monotherapy or combo therapy FB-10
Slide 4: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina
Slide 5: ~$51 Million net NERLYNX revenue in Q2'22
~$51 Million net NERLYNX revenue in Q2’22 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 50.0 51.0 51.3 48.6 48.8 49.3 48.9 45.6 45.8 43.4 40.7 36.0 20.1 6.1 Copyright 2022 Puma Biotechnology 5
Slide 6: 3,200 Ex-factory bottles were sold in Q2'22
3,200 Ex-factory bottles were sold in Q2’22 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,454 3,247 3,354 3,200 2,947 2,680 2,137 675 Includes Commercial SP and SD Copyright 2022 Puma Biotechnology 6
Slide 7: ~65% of patients in Q2'22 started at a reduced dose
~65% of patients in Q2’22 started at a reduced dose* ** % of Patients starting at reduced dose 65.4% 61.5% 59.4% 54.9% 42.4% 37.7% 38.7% 32.8% 30.0% 31.0% 28.0% 19.0% 12.0% 11.0% 6.0% 7.0% 3.0% 4.0% 2.0% 2.0% *Reduced dose defined as fewer than 6 pills per day ** FDA approved dose-escalation label s
Slide 8: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore Australia / SE Asia • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • Q2 2021 – Malaysia • Q2 2022 – Ext. Adj. in the Philippines • Q3 / Q4
Slide 9: Puma Financial Guidance for 2022
Puma Financial Guidance for 2022 NERLYNX revenue guidance: $180 to $190 million NERLYNX royalty guidance: $27 to $30 million Net income guidance: $6 to $7 million Copyright 2022 Puma Biotechnology 9
Slide 10: CONTROL Study Design
CONTROL Study Design Phase 2 trial to characterize the incidence and severity of diarrhea in patients with HER2+ early breast cancer treated with neratinib and loperamide prophylaxis ± an investigational agent 1 year of therapy HER2+ early BC Neratinib 240 mg/day (endocrine therapy as indicated) • R
Slide 11: CONTROL vs ExteNET: Neratinib Treatment-Emergent Diarrhea
CONTROL vs ExteNET: Neratinib Treatment-Emergent Diarrhea Loperamide prophylaxis reduces incidence and severity of diarrhea CONTROL1 ExteNET3 Neratinib dose Budesonide Colestipol Colestipol + escalation + Loperamide Loperamide + loperamide + loperamide loperamide prn loperamide prn prn (n=137) (n=64
Slide 12: NERLYNX Extended Adjuvant HER2+ Breast Cancer Market Size
NERLYNX® Extended Adjuvant HER2+ Breast Cancer Market Size Approximately 28,300 patients (US) with early stage HER2+ breast cancer treated with adjuvant treatment1 Approximately 6,000 patients (US) with HR positive early stage HER2+ breast cancer and no pathological complete response to neoadjuvant
Slide 13: Phase III Trial – Third-Line HER2+ MBC (NALA) Study Design
Phase III Trial – Third-Line HER2+ MBC (NALA) Study Design 3rd- or later-line therapy for patients with HER2+ mBC Patients with asymptomatic CNS metastatic disease are eligible Obtained SPA from FDA and review by EMA in February 2013 1:1 RANDOMIZATION Neratinib + Capecitabine PD HER2+ mBC Received ≥
Slide 14: NALA Study Results: Centrally Confirmed PFS
Phase III Trial – Third-Line HER2+ MBC (NALA): Study Results Centrally Confirmed PFS (co-primary endpoint) 1.0 Hazard ratio Log-rank 0.9 (95% CI) p-value 0.8 Neratinib + Capecitabine 0.76 (0.63–0.93) 0.0059 Lapatinib + Capecitabine 0.7 PFS probability 0.6 0.5 47% 0.4 38% 0.3 29% 0.2 16% 0.1 15% 7% 0
Slide 15: NALA Study Results: Restricted Means PFS
Phase III Trial – Third-Line HER2+ MBC (NALA): Study Results Prespecified restricted means analysis – PFS 1.0 Mean PFS 0.9 (months) p-value 0.8 Neratinib + Capecitabine 8.8 0.0003 Lapatinib + Capecitabine 6.6 0.7 PFS probability 0.6 Restriction: 24 months 0.5 0.4 0.3 0.2 2.2 months 0.1 0 0 3 6 9 12
Slide 16: NALA Study Results: OS
Phase III Trial – Third-Line HER2+ MBC (NALA): Study Results OS (co-primary endpoint) 1.0 Mean OS Hazard ratio Log-rank 0.9 (months) (95% CI) p-value Neratinib + Capecitabine 24.0 0.8 0.88 (0.72–1.07) 0.2086 Lapatinib + Capecitabine 22.2 0.7 OS probability 0.6 Restriction: 48 months 0.5 0.4 0.3 0.2
Slide 17: NALA Study Results: Time to Intervention for CNS Metastases
Phase III Trial – Third-Line HER2+ MBC (NALA): Study Results Time to intervention for CNS metastases 100 Neratinib + Capecitabine Lapatinib + Capecitabine 90 Intervention (n=55/307) (n=75/314) Radiation therapy 11% 15% 80 Surgery/procedure 2% 3% Cumulative incidence (%) 70 Anticancer medication 1% 1
Slide 18: Third-Line HER2+ MBC Market Size
Third-Line HER2+ MBC Market Size Approximately 6,400 patients (US) with third-line HER2+ metastatic breast cancer and 4,700 patients (US) with fourth-line HER2+ metastatic breast cancer1 1Roche epidemiology slides 09/18 Copyright 2022 Puma Biotechnology 18
Slide 19: FB-10 – Phase I/II Trial of Kadcyla (T-DM1) + Neratinib
FB-10 – Phase I/II Trial of Kadcyla (T-DM1) + Neratinib HER2+ MBC Neratinib Dose level 1: 120 mg/d Must have received prior Dose level 2: 160 mg/d anti-HER2-based therapy Dose level 3: 200 mg/d with pertuzumab for mBC Dose level 4: 240 mg/d No prior T-DM1 or HER2 T-DM1 TKI allowed 3.6 mg/kg IV d1 Q3
Slide 20: FB-10 – Phase I/II Trial of Kadcyla (T-DM1) + Neratinib
FB-10 – Phase I/II Trial of Kadcyla (T-DM1) + Neratinib 240 * 240 *Off TX, AE/withdrawn + On treatment 200 200 200 200 * 200 ORR (CR/PR): 12 of 20 (60%) 160 Dose mg/d 160 CR 160 PR 160 SD 160 PD 160 160 * 160 + 120 * 120 120 120 * 120 0 100 200 300 400 500 600 700 800 Days on Treatment Copyright 202
Slide 21: TBCRC 022: Phase II Trial of Neratinib in Brain Metastases
TBCRC 022: Phase II Trial of HKI-272 (Neratinib) for Patients with HER2+ Breast Cancer and Brain Metastases Progressive Cohort 1 (n = 40 pts) (Treat until PD or toxicity; if non-CNS PD, Neratinib (240 mg/day) brain mets trastuzumab may be added) Craniotomy candidates Cohort 2 (n = 5 pts) Neratinib (
Slide 22: TBCRC-022 Cohort 3a CNS Response
TBCRC-022 Cohort 3a CNS Response Best Volumetric Response (n=31)* Best Volumetric CNS response (n=31 evaluable pts) 100 % reduction in volume of CNS lesions 80 CNS ORR = 49% (95% CI 32–66%) 60 40 20 0 -20 -40 -60 -80 18 responses -100 Copyright 2022 Puma Biotechnology * ASCO 2017 22
Slide 23: Neratinib Included as Treatment Option for CNS Metastases by NCCN
Neratinib Included as a Treatment Option for Recurrent Breast Cancer CNS Metastases By NCCN® Guidelines1 Guidelines updated March 2020 Category 2A: Category 2B: Neratinib + Capecitabine Neratinib + Paclitaxel TBCRC 0222 NEfERT-T3,4 A Phase II Trial of Neratinib and Randomized, Multi-Center, Internat
Slide 24: Current SUMMIT 'Basket' Trial: Study Design
Current SUMMIT ‘Basket’ Trial: Study Design EGFR exon18- Neratinib EGFR, HER2 or HER4 mutations mutant tumors Lung monotherapy (documented by local testing) Cervical Primary endpoint • Objective response rate at first post-baseline tumor assessment (ORRfirst) Neratinib Salivary gland Secondary endpo
Slide 25: SUMMIT Breast Cancer Cohort
SUMMIT Breast Cancer Cohort
Slide 26: Characteristics of HER2-mutant breast cancer
Characteristics of HER2-mutant breast cancer1–8 Incidence Histology Genomics 2% Primary breast cancers Predominantly in hormone Occur across multiple domains receptor-positive (luminal-A) of the protein (KD, ECD, TMD) 2–4% MBC and HER2-negative tumors Most common variants: 8% ER+ MBC Represented in
Slide 27: Current SUMMIT breast cancer cohorts
Current SUMMIT breast cancer cohorts • Added inclusion criteria for HR+ cohort to reflect current standard of care: prior CDK4/6 inhibitor therapy HER2-mutant MBC MBC cohort Treatment assignment HR+/HER2-negative MBC Neratinib + Fulvestrant (with prior CDK4/6i) + Trastuzumab Non-randomized Neratinib
Slide 28: HR+ non-randomized N+F+T w prior CDK4/6i: Efficacy findings
HR+ non-randomized N+F+T w prior CDK4/6i: Efficacy findings Non-randomized Characteristics (N+F+T, n=26) Objective response (confirmed CR/PR)a, n (%) 12 (46.2) CR 0 PR 12 (46.2) Best overall response 15 (57.7) (confirmed or unconfirmed PR or CR), n (%) Median DORb, months (95% CI) 14.4 (6.4–NE) Clin
Slide 29: HR+ randomized cohorts: Efficacy findings
HR+ randomized cohorts: Efficacy findings Neratinib appears to be critical for inhibition of HER2 mutations Randomized cohort Characteristics (N+F+T, n=7) (F+T, n=7) (F, n=7) Objective response (confirmed CR/PR)a, n (%) 2 (28.6) 0 0 CR 1 (14.3) 0 0 PR 1 (14.3) 0 0 Best overall response 3 (42.9) 0 0
Slide 30: TNBC cohort: baseline characteristics and efficacy
TNBC cohort: baseline characteristics and efficacy TNBC TNBC Baseline characteristics (N+T, n=18) Efficacy (N+T, n=18) ECOG performance status, n (%) Objective response (confirmed CR/PR)a, n (%) 6 (33.3) 0 9 (50.0) CR 1 (5.6) 1 9 (50.0) PR 5 (27.8) Best overall response Histological type, n (%) 7 (3
Slide 31: Change in tumor size (target lesion) and characteristics
Change in tumor size (target lesion) and characteristics Non-randomized Randomized Randomized Randomized HR+ HR+ HR+ HR+ Prior CDK4/6i Prior CDK4/6i Prior CDK4/6i Prior CDK4/6i TNBC N+F+T N+F+T F+T F N+T Best overall response CR PR SD 100 HER2 mutation category PD Kinase domain hotspot Kinase domain
Slide 32: SUMMIT Cervical Cancer Cohort
SUMMIT Cervical Cancer Cohort
Slide 33: Characteristics of HER2-Mutant Cervical Cancer
Characteristics of HER2-Mutant Cervical Cancer Incidence Histology Genomics 5% metastatic cervical cancers Enriched in adenocarcinomas Most common HER2mut is S310 May be negatively prognostic for High occurrence in HPV+ tumors extracellular domain hotspot mutation survival Usually exclusive to HER2
Slide 34: Neratinib Monotherapy Results Published in Gynecologic Oncology
Neratinib Monotherapy Results Published in Gynecologic Oncology Best response Histology PIK3CA co-mutation KRAS co-mutation TP53 co-mutation Gynecologic Oncology, 2020 Copyright 2022 Puma Biotechnology 34
Slide 35: Neratinib Monotherapy Results Published in Gynecologic Oncology
Neratinib Monotherapy Results Published in Gynecologic Oncology Gynecologic Oncology, 2020 Copyright 2022 Puma Biotechnology 35
Slide 36: SUMMIT (PUMA-NER-5201) Basket Trial
SUMMIT (PUMA-NER-5201) Basket Trial EGFR exon 18 lung cancer cohort update
Slide 37: EGFR Exon 18-Mutant Lung Cancer Cohort: Efficacy Summary
EGFR Exon 18-Mutant Lung Cancer Cohort Receiving Neratinib Monotherapy: Efficacy Summary Efficacy evaluable patients TKI Pre-Treated Parameter (n=11) (n=10) Objective response (confirmed),a n 4 4 CR 0 0 PR 4 4 Objective response rate, % (95% CI) 36 (11–69) 40 (12–74) Best overall response, n 6 6 CR
Slide 38: EGFR Exon 18-Mutant Lung Cancer Cohort: Treatment Duration and Response
EGFR Exon 18-Mutant Lung Cancer Cohort Receiving Neratinib Monotherapy: Treatment Duration, Best Response and Best Change in Tumor 100 0902 (G719A) 0711 (G719X) 7902 (G719C; E709K) 50 0758 (G719X) % Change in Tumor 0712 (G719X; S768I) 1910 (G719C; S768I; T790M) 0 7904 (G719X; S768I) 1900 (G719A; E70
Slide 39: Historical Response Rates of Afatinib in NSCLC With EGFR Exon 18 Mutations
Historical Response Rates of Afatinib in NSCLC Patients With EGFR Exon 18 Mutations (G719X) TKI-naïve patients TKI-pre-treated patients Yang et al. Journal of Thoracic Oncology (2020) 15(5): 803-815 Copyright 2022 Puma Biotechnology 39
Slide 40: Puma – Expected Milestones
Puma – Expected Milestones Report Phase II data from cohort of patients in SUMMIT basket trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations (H2 2022) Conduct a meeting with the FDA to discuss the registration pathway of neratinib in HER2-mutated HR- positive breast
Slide 41: Intellectual Property
Intellectual Property Composition of matter patent issued (expires 2030) – Extended by USPTO in November 2021 per Hatch/Waxman Use in the treatment of cancer issued (expires 2025) Two polymorph patents issued (both expire 2028) Combination with capecitabine (expires 2031) Use in extended adjuvant br
Slide 42: Intellectual Property on EGFR T790M Mutations
Intellectual Property on EGFR T790M Mutations Issued claims in Europe, Asia, Australia (expires 2026) – Possibility to extend up to 5 years Issued claims in United States (expires 2026) Patent claims upheld after European Opposition Hearing (February 2014) – Patent claims upheld after Appeal to Euro
Slide 43: Experienced Management Team
Experienced Management Team Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder – Chief Executive Officer, President, Founder, Cougar Biotechnology Jeff Ludwig Chief Commercial Officer – Eli Lilly, Astellas, Amgen Maximo F. Nougues Chief Financial Officer – Getinge AB, Boston Scie
Slide 44: Board of Directors
Board of Directors Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder, Puma Biotechnology, Inc. Alessandra Cesano, MD, PhD Chief Medical Officer, ESSA Pharmaceuticals; NanoString; Cleave Biosciences; Nodality; Amgen; Biogen; SmithKline Allison Dorval CFO, Verve Therapeutics; Form
Slide 45: Puma Biotechnology – Financial
Puma Biotechnology – Financial Currently trading on NASDAQ: PBYI Cash, cash equivalents and marketable securities at June 30, 2022: ~$60.8 million Net income in Q2 2022: ~$9.4 million Cash burn in Q2 2022: ~$14 million 2022 Guidance 2022 NERLYNX revenue guidance: $180 to $190 million 2022 NERLYNX ro
Slide 46: Company Highlights
Company Highlights NERLYNX® – first HER2-directed drug approved by FDA for extended adjuvant treatment of early-stage HER2+ breast cancer in patients who have received prior trastuzumab NERLYNX® – first HER2-directed tyrosine kinase inhibitor approved in both early stage and metastatic HER2+ breast
Slide 47: Puma Biotechnology
Puma Biotechnology H.C. Wainwright 24th Annual Global Investment Conference September 2022